Published in Blood Weekly, July 14th, 2005
A formal entry of this ruling as a final judgment of the court would result in the lifting of the 30-month stay on U.S. Food and Drug Administration (FDA) approval, which has been in place since the initiation of this patent infringement suit. While Amphastar and Teva have requested marketing approval from the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.